Errol de Souza

Errol B. de Souza was the founder of Neurocrine Biosciences, Inc., founded in 1992, where the title held was Director, Executive VP-Research & Development from 1992 to 1998.
Current jobs include Chairman at Cyclerion Therapeutics, Inc. since 2021; Director at Kures, Inc.; Independent Director at Alector, Inc. starting in 2024; and Director at Bionaut Labs, Inc. Former jobs include President, Chief Executive Officer & Director at Lundbeck Research USA, Inc. from 2002 to 2003; President, Chief Executive Officer & Director at Archemix Corp.
from 2003 to 2009; President, Chief Executive Officer & Director at Biodel, Inc. from 2011 to 2016; President, Chief Executive Officer & Director at Neuropore Therapies, Inc. from 2017 to 2019; President & Chief Executive Officer at Albireo Pharma, Inc.; Chairman-Technology Committee at Merial, Inc.; Executive Chairman at nLife Therapeutics SL; Director at IDEXX Laboratories, Inc. from 2003 to 2009; Director at Palatin Technologies, Inc. from 2003 to 2010; Non-Executive Director at Bionomics Ltd. from 2008 to 2023; Independent Director at Targacept, Inc. from 2011 to 2015; Independent Director at Catalyst Biosciences, Inc. from 2015 to 2022; Independent Director at Royalty Pharma Plc from 2020 to 2026; Senior VP, Head-Research & Development at Aventis Pharmaceuticals, Inc. from 1998 to 2002; Head-CNS Diseases Research at DuPont Merck Pharmaceutical Co. from 1990 to 1992; and Senior VP, Head-Research & Development at Hoechst Marion Roussel, Inc. from 1998 to 2002.
Education includes undergraduate and doctorate degrees from the University of Toronto.